The organisers of the Giro d'Italia say they were not alerted to Chris Froome's adverse analytical finding (AAF) for excess asthma medications prior to the announcement on November 29 that he would target next year's race.
Froome was notified on September 20, 2017 that a doping control sample he gave during the Vuelta a España exceeded the WADA limit for salbutamol, an asthma drug he uses regularly.
Despite being already involved in the process of trying to demonstrate to the UCI that his values were not the result of exceeding the maximum allowed dose of his asthma inhaler, Froome stated his intentions to race the 2018 Giro d'Italia and Tour de France.
ADVERTISEMENT
RCS Sport put out an official statement on Thursday, lending its support to the UCI’s independent anti-doping wing and reiterating its denial that Froome would receive start money to compete in the race, which is due to start in Jerusalem on May 4.
"Chris Froome's decision to participate in the 2018 Giro d'Italia was his own, taken along with his team's management, and is a choice that RCS Sport, as organiser of the Giro d'Italia appreciated; no money has been paid to the rider by RCS Sport," the statement read in response to questions from the BBC.
"Both RCS Sport and the Giro d'Italia's race direction reaffirm their full support of the Cycling Anti-Doping Foundation (CADF) and will respect whatever decisions are to be taken in the future."
- Chris Froome returns adverse analytical finding for salbutamol
- Will Chris Froome's salbutamol result sink Team Sky?
- Vuelta a Espana organisers call for 'extreme caution' after Froome salbutamol result
- Nibali: Chris Froome salbutamol case is terrible for the sport
- Froome's salbutamol case and what it means for him, Team Sky and cycling - Podcast
You can read more at Cyclingnews.com
via Cyclingnews Latest News http://ift.tt/2BuzhGQ
No comments:
Post a Comment